Amgen's Imdylltra EU Approval: Incremental Positive, but Thesis Unchanged

What happened

Amgen secured EU approval for Imdylltra in extensive-stage small cell lung cancer, backed by Phase 3 data showing a 40% reduction in death risk. While this adds to Amgen's oncology growth story, the DeepValue master report maintains a POTENTIAL SELL rating, citing accelerating price/biosimilar pressure on legacy assets (ENBREL, Prolia, XGEVA), elevated leverage, and unresolved tax risk that outweigh near-term pipeline wins. The EU nod was largely anticipated and does not move the needle on the core thesis: that at ~$339, the stock already prices in mid-single-digit growth and obesity optionality, leaving limited buffer for execution misses. Imdylltra is one of several growth assets, but its contribution is too small to offset the structural headwinds facing the base business over the next 6–18 months.

Implication

The EU nod de-risks Imdylltra incrementally but does not alter the bearish skew from legacy erosion, leverage, and tax overhang. Investors should look to trim into strength above $370 or wait for a pullback below $295 for a better entry, as the base-case risk-reward is unattractive at current levels.

Thesis delta

The EU approval for Imdylltra is a marginal positive that confirms oncology execution but does not change the fundamental thesis. The key drivers remain MariTide Phase 3 data, Horizon asset growth, and the pace of legacy revenue decline. No shift in the POTENTIAL SELL stance; the stock's valuation still embeds optimistic assumptions that leave limited room for error.